miR-133a regulates Vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the Vitamin K cycle

Molecular Medicine

Volumn 18, Issue 11, 2012, Pages 1466-1472

  Pérez Andreu, Virginia ^a   Teruel, Raúl ^a   Corral, Javier ^a   Roldán, Vanessa ^a   García Barberá, Nuria ^a   Salloum Asfar, Salam ^a   Gómez Lechón, María José ^b,c   Bourgeois, Stephane ^d   Deloukas, Panos ^d   Wadelius, Mia ^e   Vicente, Vicente ^a   González Conejero, Rocío ^a   Martínez, Constantino ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 133A; MICRORNA 137; UNCLASSIFIED DRUG; VITAMIN K 2,3 EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; VITAMIN K GROUP;

3' UNTRANSLATED REGION; ALGORITHM; ARTICLE; BINDING SITE; CELL STRAIN HEK293; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; EX VIVO STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BINDING SITES; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION; GENES, REPORTER; HEK293 CELLS; HEP G2 CELLS; HUMANS; LIVER; MICRORNAS; MIXED FUNCTION OXYGENASES; MOLECULAR SEQUENCE DATA; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; THERMODYNAMICS; VITAMIN K;

EID: 84872406530     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00062     Document Type: Article

References (24)

1. Rieder MJ, et al. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352:2285-93.
2. Stafford DW. (2005) The vitamin K cycle. J. Thromb. Haemost. 3:1873-8.
3. Teichert M, et al. (2008) Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification: the Rotterdam Study. Arterioscler. Thromb. Vasc. Biol. 28:771-6.
4. Oldenburg J, Marinova M, Muller-Reible C, Watzka M. (2008) The vitamin K cycle. Vitam. Horm. 78:35-62.
5. Salem DN, O'Gara PT, Madias C, Pauker SG. (2008) Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 133:593S-629S.
6. Klein TE, et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360:753-64.
7. Perez-Andreu V, et al. (2009) Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood. 113:4977-9.
8. Bartel DP. (2009) MicroRNAs: target recognition and regulatory functions. Cell. 136:215-33.
9. Esteller M. (2011) Non-coding RNAs in human disease. Nat. Rev. Genet. 12:861-74.
10. Mishra PJ, et al. (2007) A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl. Acad. Sci. U. S. A. 104:13513-8.
11. Han M, Toli J, Abdellatif M. (2011) MicroRNAs in the cardiovascular system. Curr. Opin. Cardiol. 26:181-9.
12. Small EM, Olson EN. (2011) Pervasive roles of microRNAs in cardiovascular biology. Nature. 469:336-42.
13. Kruger J, Rehmsmeier M. (2006) RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res. 34:W451-4.
14. Teruel R, et al. (2011) Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. J. Thromb. Haemost. 9:1985-92.
15. Shomron N. (2010) MicroRNAs and pharmacogenomics. Pharmacogenomics. 11:629-32.
16. Tzur G, et al. (2009) Comprehensive gene and microRNA expression profiling reveals a role for microRNAs in human liver development. PLoS One. 4:e7511.
17. Brodersen P, Voinnet O. (2009) Revisiting the principles of microRNA target recognition and mode of action. Nat. Rev. Mol. Cell Biol. 10:141-8.
18. Chen K, et al. (2008) Polymorphisms in micro-RNA targets: a gold mine for molecular epidemiology. Carcinogenesis. 29:1306-11.
19. Ryan BM, Robles AI, Harris CC. (2010) Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer. 10:389-402.
20. Sun G, et al. (2009) SNPs in human miRNA genes affect biogenesis and function. RNA. 15:1640-51.
21. Croce CM. (2009) Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10:704-14.
22. Luo G, et al. (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 386:78-81.
23. Koos R, et al. (2009) Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. Thromb. Haemost. 101:706-13.
24. Townley-Tilson WH, Callis TE, Wang D. (2010) MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int. J. Biochem. Cell Biol. 42:1252-5.